Solutions and Recommendations

This chapter explores practical solutions for integrating psychedelic therapies into European healthcare systems. Building on the previous chapter's discussion of challenges—from regulatory issues and trial limitations to economic concerns—we now focus on concrete steps forward. Our recommendations draw from extensive stakeholder interviews and emerging trends in healthcare innovation.

Our solutions address interconnected areas: strengthening clinical evidence, enhancing economic evaluation methods, improving regulatory processes, and building treatment infrastructure. Each recommendation considers multiple stakeholder perspectives—from treatment developers and healthcare providers to regulators, insurers, and patients.

Psychedelic therapy represents a fundamental shift in mental health treatment, combining drug treatment with psychotherapeutic support in ways that challenge traditional frameworks. The integration of these novel treatments demands new approaches to healthcare coverage, regulation, and delivery systems. We examine how healthcare systems can adapt while maintaining efficiency and delivering quality care.

These treatments are still developing, and our recommendations support both their initial implementation and long-term success. With appropriate systems and policies in place, psychedelic therapy could significantly improve mental healthcare options. The solutions balance rapid progress with carefully considering safety, effectiveness, and sustainable integration.

Clinical Evidence Recommendations

The development and approval of psychedelic therapies require innovative approaches to clinical evidence generation in Europe. These treatments challenge traditional trial designs due to their unique characteristics: they often involve specialised treatment protocols alongside drug administration, have distinctive blinding challenges, and potentially have long-lasting effects that require extended monitoring.

The path forward calls for coordination among multiple stakeholders: Developers working to balance scientific rigour with practical constraints, regulators considering how assessment frameworks might adapt to these novel treatments, and evaluators examining appropriate evidence standards. Additionally, state-funded research programmes and multi-stakeholder collaborations beyond industry-sponsored trials might generate complementary evidence that addresses broader public health questions.

For Drug Developers

Key recommendations:

• Consider trial designs using active placebos and crossover studies to support robust blinding and efficient data collection.

• Implement extended follow-up periods of at least 6-12 months to track relapse rates, ongoing treatment needs, and resource use, supplemented by patient registries for long-term data collection.

• Wherever possible, compare psychedelic treatments directly against the existing standard of care (especially for the German market) to show their relative benefits and costs.

• Launch pilot programs in receptive countries like the Netherlands and the Czech Republic to generate complementary real-world evidence alongside Phase III clinical studies.

• Use validated metrics for functional recovery and quality of life while tracking broader benefits like improved work productivity, reduced hospital stays, and decreased caregiver burden to demonstrate value to healthcare systems and beyond.

• Engage with regulators and payer assessment bodies (HTA groups) during Phases II and III to align evidence collection and analyses with requirements.

Pre-Market Authorisation Trials

Drug developers must design substantial, credible trials to satisfy regulators and evaluators. Using active placebos (like low doses of the study drug) helps maintain proper blinding. Compass Pathways has already used this approach, setting a helpful example. Developers should continue the dialogue with the EMA to agree on acceptable active placebos, even though this makes trials more complex and potentially more expensive.

Crossover studies, where participants receive both treatment and placebo at different times, can be an effective trial design. These studies are efficient because each person acts as their own control. However, developers must carefully consider how long psychedelic effects last when planning these trials.

Adaptive trial designs that allow changes based on early results can save time and resources. While not yet common in psychedelic research, these designs can speed up approval by pre-agreeing potential changes with regulators. Supplementing traditional confirmatory trials with pragmatic trials and real-world data initiatives to better understand optimal treatment protocols could be particularly valuable in the early stages of psychedelic therapy development, helping to prevent suboptimal parameters from becoming regulatory standards and supporting more sustainable development of these treatments.

Trial designs should delineate and measure the contributions of both the pharmaceutical intervention and the psychotherapeutic support provided. While academic researchers may better investigate different therapeutic approaches post-approval, developers should ensure their trials can demonstrate the specific impact of their pharmaceutical intervention within their chosen treatment protocol. Lykos's recent difficulties with the FDA over their MDMA therapy for PTSD illustrate the importance of this clarity in assessing both clinical benefits and costs.

Real-world pilots—especially in countries like the Netherlands and the Czech Republic, where regulatory environments support innovation—can complement traditional clinical trials. When conducted in partnership with regulators, healthcare providers, and other stakeholders, these pilots could potentially serve as an alternative to local Phase III trials. They can generate valuable additional data on cost-effectiveness and treatment scalability while offering insights to payers and policymakers to support approval and adoption.

Post-Market Authorisation Evidence Generation

Developers need to show that treatments work both initially and over time. Clinical trials should track key outcomes like depression scores for 6-12 months after treatment. However, understanding the full impact on healthcare systems requires real-world data collection after treatments become available. Real-world data collection includes tracking relapse rates, ongoing treatment needs, and healthcare resource use in clinical practice. The resulting real-world evidence is crucial for proving value to healthcare systems, particularly in markets with strict budget constraints.

Developers should consider registry-based studies to track real-world and long-term outcomes after market entry. These studies can provide real-world evidence to supplement clinical trials, particularly for countries like Germany that may require ongoing reassessment.

Addressing Evidence Gaps for Regulators and Evaluators

Developers need to focus on evidence that aligns with HTA expectations, using validated metrics for quality of life, functional recovery, and symptom reduction rather than creating new tools. Their economic models should also capture indirect benefits like productivity gains, reduced caregiver burden, and lower hospitalisation rates. These factors are especially important in countries like the Netherlands, which may take a broader view of value. Early engagement with payers through scientific advice programs can help identify the most relevant metrics and prevent conflicting requirements between regulatory approvals and reimbursement criteria.

For many markets, particularly Germany (the largest EU pharmaceutical market), comparing new treatments to existing ones like SSRIs, augmentation therapies, or ketamine for depression is crucial for achieving reimbursement and more favourable drug pricing. Where direct comparisons aren't possible, developers must justify alternative approaches. The need for proper blinding in regulatory trials often moves study designs away from payer expectations around comparative effectiveness. Developers should engage with payers and HTA groups early to explain why true placebos or standard-of-care comparators might not be feasible, and work together to find pragmatic solutions for generating comparative effectiveness evidence. These discussions should happen during Phase II or early Phase III to avoid costly delays or rejections and to ensure trial designs meet local requirements.

For therapies with high uncertainty, conditional reimbursement or managed entry agreements that link reimbursement to real-world performance can help address payer concerns while providing earlier patient access. Starting with pilot submissions in smaller markets can help test and refine evidence packages before targeting larger countries.

For Regulators and Evaluators

Key Recommendations:

• Provide more precise guidance on trial design requirements while offering early consultation opportunities to help developers effectively plan their evidence collection.

• Support the development of standardised patient registries and outcome measures across Europe to improve the efficiency of data collection and comparison.

• Coordinate between European regulatory and reimbursement evaluation bodies to harmonise requirements and reduce duplicate work for treatment developers.

• Establish clear incentive frameworks for mental health treatments similar to successful models used for orphan drugs and pediatric medicines.

Improving Guidance and Support

Regulators and payers must provide clear, consistent guidance about the evidence they require to evaluate psychedelics. While assessment frameworks exist at both European (Joint Clinical Assessment) and national levels, with published methodological guidance, these frameworks would need updating to handle the unique aspects of psychedelic treatments, which often combine pharmaceutical interventions with specialised therapeutic protocols. Better guidance on acceptable trial designs and standards for real-world data collection will help developers plan more effectively.

A critical component is establishing clear definitions of unmet needs that recognise the significant societal burden of mental health conditions and their decades-long innovation stagnation. Following successful models used for orphan and paediatric medicines, these definitions should serve as prerequisites for accessing development incentives such as PRIME designation, accelerated assessment, conditional marketing authorisation, and additional data protection periods.

Regulators should expand early consultation opportunities, allowing developers to discuss their plans before starting patient trials. These consultations should address practical challenges like maintaining proper blinding and selecting appropriate comparators. To help more organisations participate, regulators should make these consultations more affordable or free for smaller developers. Regulators should also specify country-specific comparators, so developers can align studies with national standards of care.

Supporting Evidence Generation and Methods

Regulators and reimbursement evaluators should consider innovative trial designs, such as crossover and hybrid models, that effectively test drug-therapy combinations while addressing blinding and placebo concerns. These approaches can better evaluate individual treatment components and reduce inconclusive results. Long-term follow-ups through national or EU-level registries are essential to track treatment durability while providing real-world evidence across diverse populations.

Harmonised metrics across countries would reduce duplicate studies and facilitate data comparison. Regulators must balance flexibility in assessment with clear standards for data transparency and post-marketing surveillance. Success will require collaboration between regulators, developers, and other stakeholders to establish practical guidelines for evidence generation and create sustainable pathways that appropriately incentivise innovation in mental health treatments.

Economic Evaluation Strategies

The economic evaluation of psychedelic therapies presents unique challenges for both developers and health technology assessment (HTA) bodies in Europe. These novel treatments combine drug interventions with psychotherapy sessions, creating more complex cost structures than existing care models with higher upfront investments but with the potential for rapid clinical efficacy, medium to long-term clinical outcomes and additional societal benefits.

Success requires developers to build compelling economic models that demonstrate value within established HTA frameworks. Assessment bodies must also consider how to evaluate and reimburse these innovative treatment approaches. These parallel challenges create a shared responsibility: Developers must provide robust cost-effectiveness estimates, while HTAs must adjust their assessment frameworks to accommodate for the uncertainty arising from evidence gaps present at market entry, e.g. longer term outcomes and comparative effectiveness.

While HTA bodies may not incorporate societal benefits in their core cost-effectiveness analyses, developers should be allowed to present supplementary analyses that demonstrate these wider benefits. Including supplementary analyses would enable stakeholders to understand the full value proposition of these treatments, even if such benefits can not directly influence reimbursement decisions under current assessment frameworks.

For Drug Developers

Key Recommendations:

• Develop comprehensive economic models incorporating direct and indirect benefits to demonstrate the full set of value provided by therapies.

• Create market-specific economic models that align with national requirements and use validated metrics, particularly for markets using health economics for price and reimbursement decision-making, such as the UK and the Netherlands.

• Include scenario analyses and sensitivity testing to address treatment effects and adoption rate uncertainties.

• Evaluate market viability early by analysing each market's specific HTA requirements, cost-effectiveness thresholds, and which economic benefits (like workplace productivity) are included in reimbursement decisions.

• Engage with HTA bodies during development so that economic models meet requirements and prevent costly adjustments later.

Building Comprehensive Economic Models

Economic models for psychedelic therapies must capture both immediate and long-term impacts within European HTA methodologies. These models should include direct costs such as drug pricing, therapist fees, and facility investments, as well as exploring other benefits like productivity gains, reduced caregiver burden, and fewer hospitalisations.

Quality-adjusted life years (QALYs) remain the dominant approach, requiring validated mental health metrics that HTA bodies already accept. Comprehensive scenario and sensitivity analyses are essential to explore varying assumptions about treatment effects and uptake rates.

Navigating Market-Specific Economic Requirements

Developers must tailor their economic modeling approaches to different markets to support payer engagement and decision-making. The UK’s NICE has very specific guidance on the preferred cost-effectiveness modelling methodology and makes decisions based on cost per QALY thresholds. NICE does not include caregiver or societal benefits to calculate cost-effectiveness, although modifiers for acceptable CE thresholds exist for some conditions. The Netherlands may accept more real-world evidence and registry data and accommodate broader value into its cost-effectiveness evaluations, including work productivity.

For some markets, budget impact will be the main focus of the economic evaluation, which may include drug cost only, drug plus therapy, or all costs associated with care provision.

Strategic Planning and Engagement

Developers should evaluate each market's specific requirements and thresholds early in development to determine where reimbursement is feasible. This assessment must consider whether excluded benefits—such as workplace productivity improvements—or country-specific CE thresholds significantly impact the economic argument for treatment. Early engagement with HTA bodies can help align economic models with evaluation criteria and prevent costly redesigns later in development.

For HTA Evaluators and Payers

Key Recommendations:

• HTA groups should develop frameworks for evaluating combined drug-therapy treatments, considering long-term cost savings and societal benefits.

• To manage upfront costs and uncertainties, payers must explore innovative payment models like bundled payments and performance-based contracts.

• HTA groups and payers should collaborate early with developers to align on evidence requirements and acceptable economic models.

• HTA groups should create standardised approaches for tracking and evaluating real-world performance across European healthcare systems.

Adapting Evaluation Frameworks

To properly assess psychedelic therapies, HTAs should ensure their evaluation frameworks accommodate both drug and therapy components. Standardised methods should be developed to evaluate combined treatments, while maintaining flexibility for national requirements. HTAs can incorporate broader societal benefits by adapting existing tools for measuring indirect effects and creating new metrics tailored to mental health outcomes.

Implementing Sustainable Payment Models

For payers, we recommend exploring bundled payment systems that combine drug and therapy costs into single reimbursement packages. Performance-based contracts can help manage uncertainty by linking payment to patient outcomes. To address higher upfront costs, consider implementing staged payment models that spread costs over time while guaranteeing long-term value.

Strengthening Collaboration

Strengthen formal channels for early dialogue between HTAs, payers, and developers. These channels should include regular stakeholder meetings to align evidence requirements with practical reimbursement solutions. Creating shared outcome measures and monitoring systems will help track treatment effectiveness consistently across different healthcare systems.

Building the Evidence Base

Both HTA groups and payers should support the development of real-world evidence programs. Such programs can include creating standardised data collection protocols and establishing partnerships with academic institutions to evaluate real-world and comparative treatment effectiveness. The resulting evidence can inform future assessment criteria and refine payment models over time.

Regulatory Pathways and Policy Reforms

The successful integration of psychedelic therapies into European healthcare systems calls for a significant evolution in regulatory frameworks and policies. Current regulations, designed primarily for traditional pharmaceuticals, are likely to struggle to accommodate treatments that combine controlled substances with structured therapy sessions. These unique treatment characteristics create a complex landscape where existing rules may need updating while maintaining essential safety standards.

Addressing these challenges requires coordinated action across multiple fronts: Developers must navigate existing pathways while advocating for appropriate reforms, regulators must adapt frameworks while protecting patient safety, and policymakers must balance innovation with public health concerns. Progress depends on finding practical solutions that uphold rigorous standards while enabling access to these potentially transformative treatments.

For Drug Developers

Key Recommendations:

• Use expedited pathways like EMA’s PRIME and MHRA’s ILAP, and pursue conditional approvals to speed up the regulatory process while collecting real-world evidence.

• Consider decentralised approval approaches through national authorities before broader European expansion.

• Start early dialogue with regulators to align on trial designs and evidence requirements for these novel treatments.

• Build comprehensive data collection systems that address both regulatory and HTA requirements from the start.

Leveraging Accelerated Regulatory Pathways

Developers should prioritise expedited regulatory pathways such as EMA’s PRIME and MHRA’s ILAP, which offer faster evaluations and early feedback. These programs, combined with conditional marketing authorisations, can accelerate approvals while maintaining rigorous standards through post-launch evidence collection. Traditional pre-marketing authorisation early access programs may not be feasible for psychedelic therapies due to legal restrictions on prescribing scheduled substances. This limitation makes post-marketing authorisation access programs with robust data collection particularly crucial for generating real-world evidence and supporting broader adoption.

Leveraging Multiple Regulatory Pathways

Developers should consider both centralised and decentralised approval strategies. While the centralised EMA procedure offers broad market access, the decentralised procedure (DCP) or mutual recognition procedure (MRP) may provide alternative routes. Under these approaches, developers can obtain approval in one EU reference member state and use this as a basis for recognition in other countries. This strategy might be particularly valuable for psychedelic therapies where some countries may be more receptive to novel treatment approaches.

Enhancing Dialogue with Regulators

Regular communication with regulators through scientific advice meetings—such as the EMA’s Scientific Advice Working Party (SAWP)—helps prevent delays and align expectations. Early engagement clarifies trial designs and evidence needs, especially regarding unique challenges like placebo controls and therapy protocols. This dialogue should extend to both European and national regulators to navigate varying requirements effectively.

Beyond standard requirements, developers should prepare comprehensive safety monitoring systems specific to controlled substances. The monitoring frameworks should include detailed risk mitigation plans, therapist training protocols, and robust adverse event monitoring. These elements demonstrate a commitment to patient safety while building confidence among regulators and healthcare providers.

While meeting regulatory requirements remains the priority, developers can advance their understanding of implementing psychedelic therapies through strategic stakeholder engagement. Effective engagement includes evidence-based briefing sessions and collaborations with patient groups. Such efforts help create an environment conducive to regulatory innovation while maintaining a focus on scientific rigour and patient benefit.

For Regulators

Key Recommendations:

• Consider bifurcated scheduling models that enable medical use while maintaining controls for recreational use.

• Develop clear frameworks for post-approval evidence collection and conditional marketing authorisations.

• Strengthen coordination between national authorities to facilitate efficient mutual recognition procedures for psychedelic therapies.

• Strengthen collaboration between regulators, HTA groups, and international agencies to streamline development.

Scheduling and Access

The classification of psychedelics as Schedule I substances presents a key barrier to development. Regulators may create a bifurcated model that maintains controls while enabling medical access, similar to frameworks for ketamine and GHB (sodium oxybate, Xyrem). Explicit criteria for reclassification would give developers the confidence to invest in research while maintaining appropriate safeguards.

Additionally, regulators should consider creating specific exemptions from Schedule I requirements for researchers, as discussed in the UK, to reduce bureaucratic barriers and make it easier to conduct vital research while maintaining appropriate oversight. Such exemptions could significantly expand research capabilities without requiring full rescheduling.

Post-Approval Evidence Generation

Given the scheduling restrictions that limit pre-approval access programs, regulators should focus on developing robust frameworks for post-approval evidence collection. Conditional marketing approvals, similar to those used for oncology treatments, can enable market entry while ensuring continued evidence generation through well-designed post-marketing studies. These frameworks should clearly specify requirements for real-world evidence collection, safety monitoring, and effectiveness demonstration.

Harmonising National Approaches

While maintaining sovereign decision-making authority, regulators should work to harmonise evaluation criteria and post-approval requirements across European countries. Harmonisation supports the efficient use of decentralised and mutual recognition procedures while ensuring consistent safety standards. Regular communication between national authorities can help share early experiences with psychedelic therapy approval and monitoring, building collective expertise while respecting different national contexts.

Regulatory-HTA Collaboration

Close alignment between regulators and HTAs helps developers meet both safety and reimbursement requirements efficiently. Dedicated contact points within agencies and template protocols for combination therapies can streamline development. Joint scientific advice meetings allow developers to address regulatory and economic requirements early.

International Coordination

Collaboration between European regulators, the FDA, Health Canada, and other regulators can reduce duplicate work and speed development. This coordination should cover data sharing, evaluation methods, and post-approval monitoring. Supporting research through targeted incentives and establishing research networks can accelerate evidence generation while promoting knowledge sharing across regions.

Infrastructure and Implementation Approaches

The successful integration of psychedelic therapies into European healthcare systems requires substantial changes to existing infrastructure and implementation approaches. While clinical evidence and regulatory frameworks are crucial, the practical considerations of delivering these treatments safely and effectively at scale are equally important. This section examines the key challenges and opportunities across three stakeholder groups: healthcare systems, therapists and providers, payers, and drug developers.

The implementation challenges vary significantly across European countries due to differences in healthcare systems, existing infrastructure, and professional training requirements. However, common themes emerge around the need for dedicated facilities, trained professionals, and sustainable funding models. Addressing these challenges requires coordinated efforts between public and private stakeholders and innovative resource allocation and service delivery approaches.

For Healthcare Systems and Providers

Key Recommendations:

• Create dedicated treatment rooms with calming environments and proper safety features to support extended psychedelic therapy sessions.

• Establish partnerships between public healthcare systems, private investors, and insurers to fund facility upgrades and expansion.

• Develop plans to meet growing patient demand, including staffing needs and scheduling systems for longer sessions.

• Join existing professional networks and training programs while advocating for more accessible certification options.

• Create clear patient screening and aftercare procedures, working closely with other mental health professionals.

• Develop unified European standards for therapy delivery and therapist qualifications.

• Build relationships with local mental health services to ensure proper patient referrals and emergency support when needed.

• Document outcomes and share experiences with other providers to help develop best practices and improve treatment standards.

• Participate in multi-disciplinary working groups to define optimal and minimum acceptable care package standards.

• Support research into alternative treatment delivery models, including group therapy and other resource optimisation approaches.

Infrastructure Development

Most mental health facilities currently lack spaces suitable for extended psychedelic therapy sessions. These sessions require carefully designed non-clinical environments where patients feel safe and supported during treatments lasting several hours.

Funding and partnerships play crucial roles in infrastructure development. Working with insurance companies, government agencies, and private investors can help fund these changes without overstretching public budgets. Integrating therapy rooms into existing mental health centres improves patient access while maximising current resources. Healthcare providers can strengthen the financial case by documenting improved outcomes and reduced hospital admissions.

Treatment Package Standards

Multi-disciplinary working groups should define both optimal and minimally acceptable care package requirements. The specifications should cover treatment rooms, the therapist's involvement in preparation and integration sessions, and dosing session support. These standards ensure consistent quality while providing flexibility in implementation approaches.

Training and Professional Development

The availability of trained therapists represents a critical challenge for scaling psychedelic therapy. While several training programmes exist, none are currently recognised or accredited by national healthcare systems, creating uncertainty for both practitioners and healthcare providers. Existing programmes often have limited capacity and high costs, creating additional barriers to entry. Healthcare systems should develop standardised, accredited training programmes that combine online learning with practical experience, making certification more accessible while maintaining quality standards.

Professional development pathways need clear structure and support. Essential components include establishing supervision networks, continuing education requirements, and opportunities for specialisation. Financial support for training, such as subsidies or tax incentives, can help build workforce capacity more quickly.

Clinical Operations and Quality Assurance

Successful implementation requires careful attention to clinical operations and standardisation. Healthcare providers need clear protocols for patient screening, risk assessment, and contraindication checking. Treatment delivery must be standardised while allowing flexibility for individual patient needs.

European healthcare systems should establish unified standards for psychedelic therapy delivery, including protocols for dosing, therapy structures, and risk management. These should specify therapists' professional requirements, including qualifications, training, and ongoing education requirements. Such standards would support safe delivery while building confidence among healthcare providers and patients.

Quality assurance systems should monitor outcomes, track adverse events, and identify areas for improvement. The monitoring framework should include regular reviews of treatment protocols, supervision of therapists, and documentation of patient experiences. Professional networks can facilitate knowledge sharing and the development of best practices.

Integration and Scale-up Planning

Healthcare systems must plan carefully for service expansion. Effective planning requires coordinating between different types of providers, managing referral pathways, and ensuring adequate emergency support. Medicine management systems must meet strict regulatory requirements while remaining practical for clinical use.

Scale-up planning should consider both immediate needs and long-term sustainability. Key planning elements include workforce development, facility expansion, and financial planning. Regular evaluation of outcomes and costs helps demonstrate value to stakeholders and supports continued investment in service development.

For Payers

Key Recommendations:

• Develop billing codes and payment structures that accommodate extended therapy sessions combined with novel drug treatments, following examples like the U.S. CPT codes for psychedelic therapy.

• Create outcome-based payment models linking reimbursement to clinical improvements and reduced healthcare utilisation.

• Establish commercial access programs with real-world monitoring to evaluate cost-effectiveness before full implementation.

• Partner with providers to develop standardised outcome measures and documentation requirements for reimbursement.

Payment Structure Development

Payers must create new reimbursement frameworks for psychedelic therapy's unique combination of drug treatment and extended therapy sessions. In the U.S., drug developers have made progress by working with the American Medical Association (AMA) to establish specific Current Procedural Terminology (CPT) codes for psychedelic therapy administration and monitoring. These codes recognise the distinct requirements of psychedelic treatments, including continuous in-person monitoring during therapy.

Building on such examples, bundled payment models, covering both medication and therapy costs, could simplify administration and provide clarity for providers. Performance-based contracts that tie reimbursement to treatment outcomes may help manage uncertainty around long-term effectiveness.

Cost Management Approaches

Given substantial upfront costs, payers should explore flexible pricing models that balance access with sustainability. Potential approaches include staged payments based on treatment milestones or outcome-based pricing tied to specific clinical improvements. Early collaboration with providers and drug developers can help design practical payment structures that work for all parties.

Implementation Programs

Pilot programs offer opportunities to evaluate real-world effectiveness and refine payment models before broader implementation. These pilots can inform the development of standardised and more permanent reimbursement and documentation requirement approaches.

Quality Assurance and Monitoring

Payers should establish transparent systems for tracking outcomes and evaluating treatment effectiveness. The monitoring system should include standard outcome measures, documentation requirements, and monitoring protocols. Regular assessment of clinical results and healthcare utilisation patterns can help refine payment models and demonstrate value.

For Drug Developers

Key Recommendations:

• Focus on developing clear, practical service specifications in partnership with healthcare stakeholders, which are specific enough to reassure healthcare systems but flexible enough to allow local adaptation.

• Avoid over-engineering treatment requirements beyond regulatory mandates.

• Support retrofitting of existing healthcare facilities rather than creating separate centers of excellence.

• Maintain clear boundaries between drug development responsibilities and healthcare system implementation.

Infrastructure Support

Drug developers should resist the temptation to solve all implementation challenges themselves. Instead of creating dedicated centres of excellence, developers should provide clear guidance for adapting existing healthcare facilities. Practical guidance should include basic specifications for treatment rooms that hospitals, clinics, and mental health facilities can retrofit into their existing spaces, similar to how facilities integrate ECT suites. Using existing healthcare infrastructure will create more scalable and cost-effective solutions than building separate specialised centres.

Treatment Requirements

When designing treatment protocols, developers should avoid over-specifying requirements for therapist qualifications or treatment settings beyond what regulators explicitly mandate. A flexible approach allows for the natural evolution of treatment approaches based on real-world experience and local healthcare system capabilities.

Taking cues from other mental health treatments like opioid use disorder therapy, where psychosocial support requirements remain broadly defined, developers should provide framework guidance while allowing flexibility in implementation.

Market Development

The most effective role for developers in market development is to create clear, practical service specifications that healthcare systems can readily adapt. These specifications should define essential safety and monitoring requirements, outline basic facility needs for treatment delivery, provide guidance on staff training and qualifications, and allow for regional variation in implementation approaches. By focusing on these core elements while avoiding overprescribing specific approaches, developers can support sustainable market development without creating unnecessary barriers to implementation.

Professional Support

Drug developers should maintain appropriate boundaries in professional training and support. While they can provide essential information about their specific treatments, healthcare systems and professional bodies should lead broader therapy training and certification. Developers could provide joint funding for independent groups to develop and deliver training and certification programs. Such collaborative funding maintains the necessary separation while accelerating ecosystem development. The system-led approach ensures sustainable development of the treatment ecosystem.

Societal and Ethical Initiatives

Making psychedelic therapies work in European healthcare systems requires more than clinical evidence and proper facilities—it also means addressing broader social and ethical issues. This section looks at how healthcare providers and policymakers can help build public trust, establish ethical treatment delivery, and make these therapies available to all who need them. While earlier sections covered technical and practical matters, this section focuses on the social aspects and ethical guidelines necessary for long-term success.

Meeting these challenges requires effective collaboration among different groups. Healthcare providers must develop clear ethical guidelines and safety measures. Policymakers are important in making treatments accessible and creating supportive rules and regulations.

For Healthcare Providers

Key Recommendations:

• Develop specialised informed consent protocols that address altered states and psychological vulnerability during treatment sessions.

• Create clear boundaries and safety guidelines for therapist-patient relationships before, during and after psychedelic sessions.

• Establish real-time reporting systems for psychological adverse events and integration challenges.

• Build support networks for providers to share experiences and develop best practices for ethical challenges.

Ethical Guidelines for Altered States

Healthcare providers must develop specific protocols for working with patients under the influence of psychedelics. The protocols should include detailed informed consent procedures that explain the unique psychological risks and experiences patients may encounter. Providers must give special consideration to vulnerable populations, particularly those with trauma histories or past substance use issues.

Healthcare providers should establish comprehensive pre-treatment procedures, including thorough psychological screening and risk assessment protocols. During sessions, providers need clear guidelines for real-time monitoring of psychological states and emergency response protocols for psychological distress. Detailed documentation requirements for altered state experiences and post-session integration support planning form essential components of these protocols.

Therapeutic Boundaries and Integration

While standard medical practice defines clear professional boundaries, psychedelic therapy presents novel situations that require additional guidance. Healthcare providers need specific protocols that address appropriate therapist-patient boundaries during altered states and integration periods. These should build upon existing ethical guidelines whilst providing clear direction for physical presence, emotional support, and post-session contact. Healthcare providers should establish structured integration support systems that maintain professional boundaries while meeting patients' emotional needs following powerful experiences.

These additional ethical considerations require ongoing provider discussion to establish best practices that complement existing medical ethics frameworks. Professional networks can help providers navigate these challenges while maintaining high ethical standards.

For Policymakers

Key Recommendations:

• Create funding mechanisms to support treatment access in rural areas and for economically disadvantaged populations.

• Develop initiatives to diversify the therapist workforce and provide culturally appropriate care.

• Build decentralised care networks to reach underserved communities.

• Mandate collection of demographic data to track and address treatment access disparities.

Geographic and Economic Access

Policymakers should focus on making psychedelic therapies available beyond wealthy urban areas. Expanding access means supporting decentralised care networks that can reach different communities. Regional treatment centres can help serve more areas, following successful models used in cancer care networks across Europe.

Cultural Competency and Workforce Diversity

Making healthcare fair means addressing cultural barriers and building a diverse treatment workforce. Healthcare providers should create training programs that attract therapists from different backgrounds and develop treatment approaches that respect various cultural perspectives. Programs should include community outreach and support for multilingual services.

Data Collection and Monitoring

Good policy needs good data. Tracking who receives treatment and their outcomes helps show where services are lacking and what needs to be improved. Regular reports on demographic patterns can guide programs toward better serving all communities.

Country-Level Perspectives and Best Practices

Germany

Key Recommendations for Germany

• Strengthen Early Payer Engagement: Developers should engage with G-BA and IQWiG early to align on clinical trial endpoints, and particularly an appropriate comparator choice.

• Demonstrate Additional Therapeutic Benefit: Developers must provide robust evidence to the G-BA and IQWiG of improved patient outcomes compared to appropriate comparators in the German healthcare context.

• Implement Risk-Sharing Agreements: Developers and payers should consider using managed entry agreements tied to real-world performance metrics to address insurer concerns, particularly around high upfront costs.

• Focus on Hospital-Based Rollouts: Developers should consider prioritising the initial adoption of psychedelics within hospital inpatient and outpatient centres, where healthcare infrastructure, staffing, and funding arrangements better support high-cost, complex therapies.

• Address Infrastructure Needs: Healthcare facilities and hospitals should prepare dedicated therapy rooms and protocols to meet regulatory requirements for safety and supervision.

• Pilot Real-World Evidence Programs: Developers should develop and validate registry-based studies or post-launch monitoring programs to provide long-term data on outcomes and cost savings.

• Invest in Workforce Training and Certification: Clinical and psychiatric associations should prepare therapist training programs aligned with German standards to prepare for implementation.

• Promote Cultural and Professional Adoption: Collaborations, including psychiatric and psychotherapy associations, should develop care guidelines and professional advocates are required for psychedelic therapies.

• Develop Public-Private Partnerships: Government and private stakeholders should consider collaborations to share the financial burden of infrastructure expansion and workforce scaling.

Professional and Cultural Adoption

Despite growing interest in psychedelic therapies, conservative attitudes within Germany's psychiatric community may present barriers to adoption. Developers should launch targeted education campaigns highlighting the clinical evidence supporting psychedelics and emphasising safety profiles to address scepticism.

Engaging professional organisations like the German Psychiatric Association to co-develop guidelines and best practices will further legitimise the therapies and reduce prescriber liability concerns. Developers should also focus on building relationships with early adopters in academic and clinical settings to serve as champions for psychedelic treatments.

The positioning of psychedelics as natural compounds, particularly psilocybin, may resonate with German preferences for nature-based therapies. Developers can use this narrative while maintaining rigorous scientific messaging to gain public and professional trust.

Regulatory Framework and Clinical Pathways

Germany's regulatory framework, overseen by the Federal Institute for Drugs and Medical Devices (BfArM), provides a structured but demanding environment for psychedelic therapies. To align with Germany’s rigorous HTA standards, developers must prioritise engagement with the Federal Joint Committee (G-BA) and IQWiG early in the process. Trials should incorporate comparative effectiveness studies using SSRIs, cognitive behavioural therapy (CBT), or other appropriate comparator treatments recognised by the G-BA. Developers should also invest in naturalistic trials that reflect real-world conditions to complement RCT data and address German regulators’ emphasis on real-world applicability.

In addition, developers should anticipate and address requirements for long-term data, such as the durability of therapeutic effects and ongoing safety monitoring, which are critical for showing long-term benefits. Implementing flexible trial designs like adaptive trials and hybrid therapy models can streamline approvals while reducing uncertainty.

Evidence Generation and Monitoring Programs

Germany's health technology assessment process, led by G-BA and IQWiG, requires robust Phase III randomised controlled trial data demonstrating clear added therapeutic benefit compared to existing treatments. This comparative effectiveness evidence forms the foundation for reimbursement and pricing decisions under the AMNOG process.

While real-world evidence plays a supplementary role, particularly for long-term monitoring and safety data collection, it can not substitute for high-quality RCT results. Post-launch monitoring programs and registry-based studies can provide valuable supportive evidence and help track long-term outcomes, but developers must prioritise generating decisive Phase III trial data showing comparative effectiveness against appropriate standard-of-care treatments.

Registry-based studies and post-launch monitoring can be particularly valuable for tracking long-term safety outcomes and gathering additional supportive evidence on the durability of effect. However, these studies should be viewed as complementary to, rather than replacements for, the core Phase III evidence package required for initial assessment and reimbursement decisions.

Significant government funding initiatives demonstrate Germany's commitment to advancing psychedelic research. The Federal Ministry of Education and Research (BMBF) has invested nearly €5 million in the EPIsoDE study investigating psilocybin for treatment-resistant depression (TRD), led by the Central Institute for Mental Health in Mannheim. This government backing extends beyond clinical trials, including acceptance studies and broader implementation research.

The upcoming Dimension Study, supported by the Federal Agency for Disruptive Innovation (SPRIN-D), exemplifies Germany's strategic approach to generating robust evidence through public-private partnerships. Other European governments and research institutions can adopt these partnership models for evidence generation and stakeholder engagement in their markets.

Reimbursement Strategies and Financial Modelling

Germany’s statutory health insurance (GKV) mandates that therapies must demonstrate added benefit compared to standard treatments to achieve a price premium over the standard of care. Demonstrating added benefit will be important given that the standard of care for many mental health conditions will be low-cost generic drugs, and a higher price will be required for commercial feasibility. Given the higher costs associated with psychedelic therapy, robust pharmacoeconomic analyses showing long-term cost savings, such as fewer inpatient admissions and lower relapse rates, may be helpful for argumentation with payers.

Risk-sharing agreements and managed entry models may offer opportunities to address payer concerns about initial costs. These agreements tie reimbursement to observed outcomes, enabling developers to negate uncertainties while demonstrating value. To strengthen economic arguments, developers may also highlight potential reductions in other treatment usage and hospitalisations, an example being the reduction in ECT use and readmission rates observed with esketamine for TRD patients in German hospitals.

Adoption within outpatient departments associated with specialist psychiatric hospitals is a pragmatic entry point, as hospitals have established funding mechanisms for managing high-cost therapies. These settings also allow for controlled implementation, rigorous data collection, and alignment with clinical protocols. Over time, this approach can pave the way for broader outpatient adoption. However, it is important to recognise that the funding and reimbursement model for the private physician-led outpatient clinics in Germany is extremely cost-constrained. Specific arrangements will need to be set up with insurers to allow private outpatient clinics to receive predictable reimbursement for the combination of a high-cost drug, extended therapist time, and the initial patient evaluation and management.

Workforce Development and Infrastructure

Scaling psychedelic therapies in Germany may require significant investments in workforce training and infrastructure. Clinical and psychiatric associations should lead the establishment of certification programs for therapists, with developers participating in these discussions to ensure alignment with treatment protocols while maintaining German clinical standards. Competency-based training modules, modelled after frameworks used for CAR-T therapies, could accelerate adoption while maintaining quality.

Addressing infrastructure gaps is equally important. Developers, health system stakeholders and policymakers may wish to collaborate to design and fund dedicated therapy rooms that meet regulatory safety, privacy, and supervision standards. Pilot programs demonstrating scalable facility designs could serve as models for larger rollouts.

Given the lengthy session times required for psychedelic treatments, healthcare providers must explore alternative delivery models to optimise resource use. Approaches such as group therapy settings or multi-patient supervision could help mitigate workforce constraints and improve cost-efficiency. Healthcare administrators should evaluate these options while maintaining safety and therapeutic effectiveness.

Public-Private Collaboration and Policy Support

Developers should pursue public-private partnerships with insurers, government bodies, and private investors to overcome infrastructure and funding barriers. These collaborations can support facility upgrades, training programs, and data collection efforts while sharing financial risks.

Policymakers should be encouraged to provide subsidies or tax incentives for infrastructure investments, similar to initiatives used for oncology and rare disease therapies. Engaging progressive political groups like the Green Party could help build momentum for policy reforms and funding support.

United Kingdom

Key Recommendations for the United Kingdom (UK)

• Leverage Accelerated Regulatory Pathways: Developers should utilise the Innovative Licensing and Access Pathway (ILAP) to allow for accelerated alignment with regulatory and NHS bodies.

• Engage Early with NICE and NHS England: Developers should initiate early dialogues with NICE and the SMC to clarify evidence requirements, cost-effectiveness modelling acceptability, and HTA expectations, ensuring alignment with payer priorities.

• Utilise the Innovative Medicines Fund (IMF): Where relevant, NHS England and developers should explore the potential for temporary reimbursement mechanisms through the IMF to enable early patient access while gathering additional real-world evidence to address uncertainties in longer term outcomes.

• Demonstrate Comparative Effectiveness and Cost Effectiveness: Developers should conduct head-to-head trials where feasible to compare psychedelic therapies with standard-of-care treatments to meet NICE and SMC preferences for direct comparisons and incremental cost-effectiveness analyses.

• Incorporate Long-Term Follow-Up Studies: Developers, in collaboration with NHS research networks, should build robust longitudinal datasets to address uncertainties about the durability of effects and economic sustainability over time.

• Develop Flexible Reimbursement Models: NHS England and developers should collaborate on outcome-based pricing and risk-sharing agreements to alleviate payer concerns about high upfront costs and scalability.

• Invest in Infrastructure and Workforce Development: NHS trusts should lead the retrofitting of facilities and creation of dedicated therapy rooms, while professional bodies should establish appropriate training programs for therapists and clinicians.

• Pilot Scalable Delivery Models: NHS trusts and clinical networks should evaluate alternative approaches, such as group therapy or hybrid treatment protocols, to manage costs and address capacity constraints.

• Build Partnerships for Implementation Pilots: NHS trusts, in collaboration with developers, should launch pilot programs to refine care pathways, inform economic models, and demonstrate real-world effectiveness before national rollouts.

Regulatory and Policy Engagement

The UK's regulatory framework, particularly the Innovative Licensing and Access Pathway (ILAP), aims to help accelerate market approvals and market access for promising therapies. Developers should actively pursue an ILAP designation, as five developers[26]1 have successfully done, to gain early dialogue with health system stakeholders and optimise the clinical programme to improve the likelihood of regulatory approval. Through ILAP, developers can meet with NHS and NICE representatives to plan how to integrate their innovative products into the existing UK health system and establish new treatment services. Engagement with NICE and NHS England is equally critical. Developers should seek early NICE advice to align clinical trial designs and economic models with the stringent evaluation methods. NICE's scientific advice services offer valuable opportunities to clarify evidence requirements and ensure trial designs capture payer-relevant outcomes.

The NHS’s Innovative Medicines Fund (IMF) presents an opportunity for developers to secure conditional market access while collecting further data. Entry is limited to products demonstrating potential for significant clinical value and potential for cost-effectiveness, with NICE and NHS England gatekeepers to this funding pathway. Policymakers should consider expanding similar mechanisms to accommodate psychedelic therapies, particularly for conditions with high unmet needs like PTSD and TRD.

Clinical Trial Design and Evidence Generation

To secure reimbursement in the UK, psychedelic therapies must demonstrate comparative effectiveness. Developers should focus on head-to-head trials against existing treatments where feasible, aligning with NICE’s preference for incremental cost-effectiveness analysis. If this is not feasible, ensure trial designs allow indirect treatment comparisons that meet NICE’s expectations. Trials should also prioritise endpoints that reflect real-world patient outcomes, such as reduced hospitalisations, improved quality of life, and lower caregiver burdens.

Long-term follow-up studies are essential to address concerns about the sustainability of benefits. Developers should design longitudinal studies to capture data on relapse rates, continued medication use, and healthcare resource utilisation over time.

Real-world evidence generation can also support HTA evaluations by validating trial outcomes in clinical settings. Registry-based studies conducted within NHS trusts could provide additional insights into scalability and cost-effectiveness. Policymakers should incentivise such initiatives to build confidence in these therapies.

Economic Modelling and Reimbursement Strategies

NICE’s strict cost-effectiveness thresholds pose challenges for psychedelic therapies, which often involve high upfront costs, including new healthcare infrastructure. Developers should create economic models that capture both clinical benefits and estimate any possible direct healthcare savings. The relatively low cost of generic ketamine (below £3 per vial) presents a significant advantage compared to proprietary treatments like Spravato, potentially allowing for cost-effective implementation when infrastructure and staffing requirements are addressed appropriately.

Developers should propose outcome-based and pay-for-performance reimbursement models to NHS payers to alleviate payer concerns and allow a shared risk approach to the roll-out of psychedelic therapies. These agreements tie reimbursement to demonstrated outcomes, ensuring the NHS only pays for therapies that deliver measurable benefits. Developers should propose Managed Access Agreements (MAAs) as a transitional solution to enable early adoption while generating supporting data.

Policymakers can facilitate integration by considering if greater use of bundled payment structures can be implemented that combine drug and therapy costs, simplifying reimbursement and enabling scalable implementation.

Infrastructure and Workforce Development

Expanding the NHS's capacity for psychedelic therapies requires investments in infrastructure and workforce training. NHS facilities may need to retrofit existing mental health facilities to include therapy-specific rooms and monitoring environments. Developers should partner with the NHS to develop a service specification for their therapy. NHS trusts should consider collaborating with developers to determine the most cost-efficient way to prepare rooms and potentially consider 3rd party providers to ensure scalability.

Workforce development is equally important. Training institutions should expand certification programs to train therapists in psychedelic protocols, including safety monitoring and integration sessions. Continuing education programs can update practitioners on emerging best practices and regulatory changes.

Alternative delivery models like group therapy and hybrid approaches could improve accessibility while reducing costs. Pilot programs should evaluate these strategies within NHS settings before broader rollouts.

Next Steps for Implementation

NHS trusts should launch pilot programs to integrate psychedelic therapies, refine care pathways, confirm clinical outcomes in real-world settings, and validate economic models. These pilots can assess scalability, cost-effectiveness, and patient outcomes, providing the foundation for national adoption.

The Ketamine Clinical Treatment Pilot in England at Central and North West London Foundation Trust provides an informative example of how to integrate new treatments into existing care pathways while minimising infrastructure and implementation challenges. This pilot utilises standard NHS mental health outcome measures (including PHQ-9, GAD-7, and Work and Social Adjustment Scale) to track patient progress, using existing NHS data systems and facilitating comparative effectiveness analysis. The program's approach of providing 5-7 ketamine doses, when patients are already receiving talking therapy, offers a structured treatment protocol that can be evaluated for both clinical efficacy and cost-effectiveness within the NHS framework.

Policymakers should prioritise legislative reforms to simplify licensing and controlled substance requirements for psychedelics with approved marketing authorisations, enabling broader clinical use. Collaboration between developers, researchers, and payers will be essential to building sustainable frameworks for these treatments.

Netherlands (NL)

Key Recommendations for the Netherlands

• Leverage Progressive Drug Policies: Healthcare policymakers should build upon the Netherlands' liberal stance on drug policy to establish frameworks for integrating psychedelic therapies into healthcare settings.

• Expand Training Programmes: Professional medical associations, in consultation with academic institutions, should develop accessible, standardised, and accredited training curricula for therapists, ensuring a scalable workforce to deliver psychedelic therapies.

• Pilot Real-World Evidence Studies: Healthcare providers and academic medical centres should utilise the existing network of clinics to conduct pragmatic trials, gathering real-world evidence to inform HTA submissions and reimbursement frameworks.

• Engage Zorginstituut Nederland (ZiN) Early: Developers should collaborate with ZiN two years before market entry to align on cost-effectiveness models, budget impact evaluations, and trial designs that meet local requirements.

• Address Affordability Concerns: Health insurers and developers should collaborate on pricing and reimbursement strategies, including bundled payments and partial reimbursement models, to reduce patient out-of-pocket costs while demonstrating economic value.

• Use Legal Pathways: Healthcare providers and researchers should leverage the three available routes (compassionate use, doctor's certificate, naturalist research) while developers work toward regulatory registration.

• Public Education and Advocacy: Professional medical societies and patient advocacy groups should lead campaigns that address stigma, differentiate clinical therapies from unregulated approaches, and promote evidence-based narratives about safety and effectiveness.

Current Legal Framework

The Netherlands provides three distinct pathways for implementing psychedelic therapies before achieving regulatory approval. Compassionate use creates opportunities for experimental treatments in cases where conventional approaches have failed, though this route is limited to substances already in clinical trials. The doctor's certificate pathway enables individual prescriptions under the Healthcare Inspectorate's (IGZ) oversight but carries significant administrative requirements. Most promising is the naturalist research route, which requires an Opium Act exemption from the Ministry of Health but allows for broader implementation and systematic data collection.

These pathways reflect the Netherlands' historically progressive stance on drug policy while maintaining necessary regulatory controls. The recent MDMA State Committee report confirms these routes as viable options, though each presents distinct challenges in terms of scalability and administrative burden.

Working with Regulators and Payer Groups

Early and sustained engagement with Zorginstituut Nederland (ZiN) is essential for successful implementation. ZiN's evaluation framework centres on four fundamental criteria: effectiveness, cost-effectiveness, necessity, and feasibility. Successful integration requires developers to present comprehensive evidence packages addressing each criterion, particularly emphasising long-term healthcare cost implications and societal benefits.

Engagement should begin at least two years before intended market entry, allowing time to address regulatory concerns and adapt protocols to meet Dutch healthcare standards. This timeline also enables developers to conduct additional studies if needed to address specific ZiN requirements, particularly around cost-effectiveness in the Dutch context. Developers should specifically align with ZiN on the inclusion of indirect benefits in cost-effectiveness modelling, such as productivity gains and reduced caregiver burden, as the Netherlands uniquely considers these broader societal impacts in their value assessments.

Training and Workforce Development

The current landscape of therapist training in the Netherlands shows promise and limitations. The OPEN Foundation's ADEPT programme represents an important first step in establishing structured training protocols. However, significant questions remain about how much of this training will be recognised by medical authorities once formal implementation begins. The program's current status as 'educational' rather than professionally accredited highlights the need for further development of training standards.

Cost and Coverage Solutions

Implementing sustainable financing models requires careful consideration of the Dutch healthcare system's unique characteristics. Innovation in payment structures is essential, with several potential approaches deserving exploration.

Outcome-based payment agreements could link reimbursement to treatment effectiveness, helping to manage financial risk for insurers. Bundled payment systems might combine therapy and medication costs into single packages, either for a course of psychedelic treatment or for a 6-12 month period of care for a specific condition, simplifying administration and potentially reducing overall costs.

The development of these payment models should account for both direct treatment costs and longer-term healthcare savings. The economic analysis should capture reduced hospitalisations, decreased medication use for chronic conditions, and improved workforce participation among successfully treated patients. Early pilot programs with insurers could help demonstrate the viability of these approaches while generating data to support broader implementation.

Research Implementation

Pragmatic research programs represent the most promising path forward. They offer a balanced approach to treatment delivery and evidence gathering. These programs can operate at a larger scale than compassionate use or individual doctor's certificates while maintaining scientific rigour through structured data collection and analysis.

Implementation should focus on creating a network of research sites to deliver treatments while systematically gathering data on outcomes, safety, and cost-effectiveness. This approach allows for developing best practices specifically suited to the Dutch healthcare context while building the evidence base needed for broader implementation.

Long-term follow-up studies should be integrated into these programs from the start, tracking clinical outcomes and broader measures of social functioning and economic impact. This comprehensive approach to data collection will help address remaining questions about long-term effectiveness and safety while providing valuable insights for future implementation efforts.

Czech Republic (CZ)

Key Recommendations for the Czech Republic

• Engage Regulators for Pathway Clarifications: Developers should work closely with SÚKL and other regulatory bodies to clarify approval pathways and adapt submission requirements for psychedelic therapies.

• Leverage Real-World Evidence: Healthcare providers and academic institutions should implement registry-based and observational studies to provide evidence that supports long-term safety and efficacy.

• Develop Risk-Sharing Agreements with Payers: Health insurance funds and developers should collaborate on innovative reimbursement contracts tied to patient outcomes to mitigate concerns about cost and efficacy.

• Expand Public-Private Partnerships: The Ministry of Health should encourage and facilitate partnerships between government bodies, research institutions, and private organisations to fund and conduct clinical trials.

• Enhance Training Infrastructure: Professional medical associations, in collaboration with academic institutions, should establish certification programs and workforce development initiatives to address therapist shortages and ensure high-quality delivery.

• Position Czech Republic as a Research Hub: The Ministry of Health and academic institutions should build on existing expertise and facilities to make the country a centre for psychedelic research and pilot programmes in Europe.

• Pilot Expanded Access Programs: SÚKL and healthcare providers should establish early access frameworks for treatment-resistant cases to build acceptance and collect data for broader adoption.

• Highlight Economic Benefits: Developers, health insurance funds, and research institutions should conduct economic evaluations to showcase cost savings and to strengthen reimbursement arguments with evidence of reduced hospitalisations and productivity gains.

• Address Regional Disparities: The Ministry of Health and regional authorities should develop policies that support equitable access, including funding grants or subsidies for rural and underserved populations.

Regulatory Framework and Research

The Czech Republic presents unique opportunities for advancing psychedelic therapy implementation, building on its established research infrastructure and progressive drug policies. The country's demonstrated capacity for innovation in medical research, particularly through institutions like the Prague Clinical Research Center, provides a strong foundation for expanding these treatments.

Early engagement with SÚKL (State Institute for Drug Control) and payers will be crucial for establishing apparent approval and reimbursement pathways. The regulatory body has shown flexibility while maintaining rigorous safety standards, creating an environment where innovation can thrive with appropriate oversight. Developers should work closely with SÚKL to clarify requirements for combined drug-therapy treatments, focusing on streamlining approval processes without compromising safety standards.

Evidence Generation and Implementation

Real-world evidence collection represents a critical next step for gaining broader acceptance and reimbursement. Registry-based studies and pilot programs, particularly those focusing on treatment-resistant conditions, can help gather essential data on long-term outcomes and cost-effectiveness. The Prague Clinical Research Center is well-positioned to coordinate these research efforts and establish best practices, drawing on its extensive experience with psychedelic research protocols.

Cost and Coverage

The Czech Institute of Health Information and Statistics highlights growing financial pressures on the healthcare system, driven by rising personnel costs, an increasing prevalence of both chronic and acute illnesses, and the escalating expenses associated with healthcare innovations. These factors are placing significant strain on the sustainability of the healthcare insurance system. As a result, the Czech healthcare system's emphasis on economic justification requires careful attention to cost and coverage strategies.

Successful implementation will depend on developing innovative payment models that demonstrate clear cost savings compared to existing treatments. The economic analysis should include documentation of reduced hospitalisation rates and decreased long-term medication use where relevant. Outcome-based payment models could help address initial concerns about treatment costs whilst providing value for the healthcare system.

Infrastructure Development and Training

Infrastructure development presents both challenges and opportunities. While major cities have some existing infrastructure through ketamine clinics, broader implementation requires significant investment in specialised treatment facilities and training programmes. This expansion should focus on creating regional treatment centres and supporting rural healthcare providers to ensure equitable access to care.

Access beyond Prague and other major cities requires carefully coordinated solutions that address both infrastructure and workforce needs. The path forward likely involves a combination of approaches, including mobile treatment teams, partnerships with regional hospitals, and specialised training programmes for local healthcare providers.

While the Czech Republic has strong medical expertise, dedicated training for psychedelic therapy needs development through partnerships with international organisations and local medical institutions. These programmes should build on existing medical training frameworks while incorporating specific protocols for psychedelic therapy. Remote support services could complement in-person treatment, helping to extend the reach of specialised care teams while maintaining treatment quality, particularly in areas where establishing full-scale treatment centres may not be immediately feasible.

Other Emerging Regions

Insights from Global Leaders in Psychedelic Therapy

Several regions outside the EU and UK—Australia, Switzerland, the United States, and Canada—have adopted progressive approaches to psychedelic therapy research, regulation, and implementation. These countries provide valuable lessons on regulatory frameworks, evidence generation, and access models that could inform European strategies for psychedelic therapies.

Australia: Early Adoption Through Medical Rescheduling

Australia became the first country to formally reschedule MDMA and psilocybin for medical use in 2023, allowing authorised psychiatrists to prescribe them for PTSD and TRD, respectively. While this regulatory change created a framework for medical access, implementation has faced significant practical challenges.

The Australian model offers important insights, particularly around training requirements for prescribing clinicians and systems for tracking outcomes. Their psychiatry-led approach to policy reform could serve as an example for European countries looking to use existing mental health networks for psychedelic therapy.

However, Australia's experience also reveals key challenges. Treatment costs remain high due to the extensive protocol and lack of structured reimbursement. So far, only dozens of patients have received treatment under the new system. European healthcare systems, particularly those with universal coverage, can learn from this by planning early for reimbursement and accessibility issues.

Switzerland: Incremental Progress with Compassionate Use

Switzerland has a long history of psychedelic research, with five physicians receiving permission to prescribe LSD and MDMA therapy from 1988 to 1993 and later maintaining partial acceptance of substances like LSD and psilocybin under compassionate-use programs since 2014. This regulatory approach has supported patient-specific exemptions, enabling therapies outside standard approval pathways.

Swiss regulators have prioritised clinical evidence generation through partnerships with academic institutions like the University of Zurich, which has spearheaded trials on psilocybin’s efficacy in treating depression and anxiety. These studies provide insights into balancing safety protocols with flexible access mechanisms.

European policymakers can draw inspiration from Switzerland’s decentralised pilot programs, which allow evidence collection while gradually expanding access. However, scalability remains a challenge, as compassionate-use models may be difficult to implement on a broader scale, as this framework is on a per-patient basis.

United States: Accelerated Pathways

The United States has led the way in using Breakthrough Therapy designations from the FDA, speeding up the review of psychedelic drugs like MDMA and psilocybin. The Breakthrough Therapy designation has fast-tracked Phase III trials and brought these treatments closer to full approval.

Beyond regulatory advances, several U.S. states now see broader insurance coverage for ketamine. More Medicaid programs and private insurance providers are reimbursing this treatment, which improves patient access and signals the growing acceptance of psychedelic therapies.

European regulators could copy some of these strategies by creating pilot programmes or trying conditional reimbursement pathways, especially in countries such as the Netherlands, where there is already experience with managed entry agreements, and insurers have shown flexibility in reimbursement models. By taking these steps, Europe can enable new treatments to reach patients quickly while still gathering essential evidence for safety and effectiveness.

At the same time, high out-of-pocket expenses and uneven access remain problems in the U.S., reminding Europe to focus on affordability and integration into public healthcare systems.

Canada: Controlled Access with Emphasis on Research

Canada has developed a two-track system for psychedelic therapies, combining clinical trials with compassionate access through Health Canada's Special Access Program (SAP). While this allows treatment for patients with severe, treatment-resistant conditions, initial SAP approvals faced significant delays.

Canada's data collection and trials approach, supported by organisations like MAPS Canada, provides valuable lessons for Europe. However, the country continues to face challenges with regional access differences and cost coverage within its public health system.